论文部分内容阅读
目的探究曲美他嗪联合三磷酸腺苷治疗冠心病合并心功能不全的临床价值。方法 120例冠心病合并心功能不全患者,随机分为实验组和对照组,每组60例。对照组采用曲美他嗪治疗,实验组在对照组治疗的基础上使用三磷酸腺苷。对两组患者的治疗效果进行比较分析。结果实验组患者心功能改善总有效率为88.3%,心电图改善总有效率为80.0%,对照组患者心功能改善总有效率为63.3%,心电图改善总有效率为58.3%,两组比较差异有统计学意义(P<0.05)。实验组患者精神状态、心慌、胸疼、呼吸困难以及生活质量评分均明显优于对照组(P<0.05)。结论曲美他嗪联合三磷酸腺苷治疗冠心病合并心功能不全效果显著,值得临床推广使用。
Objective To investigate the clinical value of trimetazidine combined with adenosine triphosphate (ATP) in the treatment of coronary heart disease complicated with cardiac dysfunction. Methods 120 cases of coronary heart disease with heart failure patients were randomly divided into experimental group and control group, 60 cases in each group. The control group treated with trimetazidine, experimental group in the control group based on the use of adenosine triphosphate. The treatment effect of two groups of patients were compared. Results In the experimental group, the total effective rate of heart function improvement was 88.3%, the total effective rate of ECG improvement was 80.0%, that of the control group was 63.3%, and the total effective rate of ECG improvement was 58.3% Statistical significance (P <0.05). The mental state, palpitation, chest pain, dyspnea and quality of life in the experimental group were significantly better than those in the control group (P <0.05). Conclusion Trimetazidine combined with adenosine triphosphate in treatment of coronary heart disease complicated with cardiac insufficiency is worthy of clinical promotion.